Who Owns Rocket Pharma Company?

Rocket Pharma Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Rocket Pharmaceuticals?

Understanding the ownership of a company like Rocket Pharmaceuticals is key to grasping its strategic direction. This is especially true for a clinical-stage biotech firm focused on rare diseases, particularly in light of recent market shifts.

The ownership landscape of Rocket Pharmaceuticals, Inc. is a critical factor influencing its governance and future. As of August 20, 2025, the company has a market capitalization of approximately $405 million, with 108 million shares outstanding. A significant portion, 98.37%, is held by 409 institutional owners, indicating a strong presence of investment firms and funds.

The company, founded in 2015 and incorporated in 1999, is dedicated to developing gene therapies for rare diseases. Its mission is to provide curative treatments for conditions with high unmet medical needs. This focus on innovation is central to its identity, even as it navigates challenges such as the May 2025 clinical hold on its RP-A501 trial for Danon disease, which led to a 62% stock price decline and subsequent litigation. Investors closely watch developments, including those related to its pipeline, such as the potential of its gene therapy for conditions like those addressed by Rocket Pharma PESTEL Analysis.

Rocket Pharma was established in late 2015 by experienced professionals from major pharmaceutical companies. The company's current biotechnology focus began in 2015, though the legal entity was incorporated earlier. Key figures in its founding and early leadership include CEO and Director Dr. Gaurav Shah and Chairman of the Board Dr. Roderick Wong.

Founding Team Expertise

The company was founded by veterans from leading pharmaceutical organizations. This brought significant industry experience to the early stages of Rocket Pharma.

Early Investment Backing

RTW Investments played a crucial role in identifying early gene therapy programs. This investment firm's involvement was key to the company's initial direction.

Initial Funding Round

Rocket Pharma's first funding round took place on January 15, 2016. Early institutional investors included Colt Ventures, Frazier Healthcare Partners, and New Leaf Venture Partners.

Path to Public Markets

The company went public through a reverse merger in 2018. This strategic move allowed for quicker access to capital markets.

Reverse Merger Details

The reverse merger was with Inotek Pharmaceuticals, a company focused on eye drug development. This transaction shaped the early public ownership structure.

Ownership Structure Evolution

While specific initial equity percentages for founders are not detailed, the company's public listing via reverse merger significantly influenced its early ownership landscape.

The initial ownership structure of Rocket Pharma is not precisely detailed with specific equity percentages for individual founders at its inception. However, the company secured early backing from institutional investors, notably RTW Investments, which was instrumental in identifying potential gene therapy programs. The first funding round occurred on January 15, 2016, with other early institutional investors including Colt Ventures, Frazier Healthcare Partners, and New Leaf Venture Partners. A pivotal moment in its early ownership history was the company's transition to public markets. This was achieved not through a traditional Initial Public Offering (IPO), but via a reverse merger in 2018 with Inotek Pharmaceuticals, a company that was developing eye drugs. This strategic maneuver provided Rocket Pharma with rapid access to capital markets, a move that fundamentally shaped its initial public ownership. For more on the company's journey, see the Brief History of Rocket Pharma.

Early Ownership and Funding

Rocket Pharma's early ownership was shaped by its founding team and initial institutional investors. The company's strategic decision to go public via a reverse merger in 2018 was a key event.

• Founders: Dr. Gaurav Shah and Dr. Roderick Wong
• Early Institutional Investors: RTW Investments, Colt Ventures, Frazier Healthcare Partners, New Leaf Venture Partners
• Public Market Entry: Reverse merger with Inotek Pharmaceuticals in 2018
• Focus: Cell and gene therapy

Rocket Pharma SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Rocket Pharmaceuticals, Inc. transitioned to a publicly traded entity in 2018 via a reverse merger, building upon its 2015 operational inception. While its NASDAQ listing is noted for February 18, 2015, this date likely pertains to the preceding entity before its specialization in gene therapy. A significant ownership shift occurred with a public offering on December 11, 2024, which generated net proceeds of $182.5 million.

As of June 30, 2025, institutional investors collectively manage a significant portion of Rocket Pharmaceuticals, with 409 entities holding 106,141,928 shares, representing 98.37% of institutional holdings. This concentration of ownership among major shareholders, including RTW Investments, LP, BlackRock, Inc., and The Vanguard Group, Inc., underscores their substantial influence on the company's strategic direction and governance. Insider ownership, comprising executives and board members, accounted for 3.34% as of May 2025, with CEO Dr. Gaurav Shah directly holding 1.11% of the company's shares, valued at $3.47 million. Understanding who owns Rocket Pharma is key to grasping its operational and strategic trajectory, particularly in the competitive biotechnology sector focused on gene therapy and rare disease treatments. The Growth Strategy of Rocket Pharma is intrinsically linked to the confidence and investment from these key stakeholders.

Key Ownership Insights

Institutional investors are the dominant force in Rocket Pharma's ownership structure, holding nearly all institutional shares. Key leadership also maintains a notable direct stake.

• Rocket Pharma is publicly traded on NASDAQ.
• Institutional investors hold over 98% of institutional shares.
• RTW Investments, LP is the largest institutional shareholder.
• CEO Dr. Gaurav Shah holds a direct ownership stake.

Rocket Pharma PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors at Rocket Pharmaceuticals, Inc. includes a blend of executive, founder, and independent members, aiming for diverse expertise and stakeholder representation. As of 2025, the board is chaired by Dr. Roderick Wong, with Dr. Gaurav Shah serving as CEO and Director. Other directors include Carsten Boess, Dr. Elisabeth Bjork, Pedro Granadillo, Dr. Gotham Makker, Dr. Michael Dolsten, Dr. Fady Malik, Piratip Pratumsuwan, and David Southwell.

The average tenure of the board members is approximately 7.6 years, indicating a degree of experience within the leadership. While specific voting structures like dual-class shares are not publicly detailed, a one-share-one-vote system is generally implied for common stock in the absence of such disclosures. This structure is typical for publicly traded companies, influencing how Rocket Pharma ownership is distributed and exercised.

Governance Challenges and Stock Impact

Rocket Pharmaceuticals has recently encountered significant governance issues. These concerns have led to substantial market reactions and legal scrutiny, impacting investor confidence and the company's valuation.

• Securities litigation filed in May 2025 alleged concealment of a critical clinical trial protocol amendment for RP-A501.
• This amendment was reportedly linked to a patient fatality and an FDA clinical hold.
• Lawsuits, including Ho v. Rocket Pharmaceuticals, Inc. and Yankov v. Rocket Pharmaceuticals, Inc., accuse the company of misleading investors and inflating stock prices.
• These events contributed to a 62% stock price collapse in May 2025.
• The situation highlights potential governance failures and their direct impact on Rocket Pharma stock.

Rocket Pharma Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Rocket Pharma has seen significant shifts in its ownership and strategic direction, notably its public offering in December 2024. This event brought in substantial capital but also led to an increase in outstanding shares, impacting existing shareholders.

The company's ownership trends reflect broader biotech sector dynamics, including a high level of institutional investment and the influence of activist investors. With 409 institutional investors holding a considerable stake, the company's trajectory is closely watched by major financial entities. Recent securities litigation highlights the increasing use of legal avenues for investor recourse in this volatile industry.

Institutional Investor Influence

Rocket Pharma has a significant presence of institutional investors, with 409 entities holding a substantial portion of its shares. This indicates a broad interest from large financial institutions in the company's potential.

Strategic Reprioritization

Following a period of stock decline and restructuring, the company is focusing its efforts on its late-stage AAV cardiovascular gene therapy programs. This strategic shift aims to optimize resource allocation and advance key pipeline assets.

Capital Management and Runway Extension

The company implemented a restructuring in Q2 2025, including a 30% staff reduction. This move is designed to reduce cash burn by 25% and extend its operational runway into Q2 2027, ensuring continued development of its gene therapy treatments.

Market Volatility and Litigation Impact

The company's stock experienced significant volatility, dropping over 85% in the year leading up to August 2025. This was exacerbated by a 62% fall in May 2025 due to a clinical hold and subsequent lawsuits, underscoring the risks associated with gene therapy development and Target Market of Rocket Pharma.

Rocket Pharma Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔